The number of microvessels per myocyte in the heart increased during the hypertrophic phase, inhibiting angiogenesis-promoting factors, such as vascular endothelial growth factor (VEGF); angiopoietin-I suppressed cardiac hypertrophy, and worsened cardiac dysfunction. Here, VEGFA is linked to cardiac hypertrophy.